Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Barbara Horváth
University Medical Center Groningen, NL
Principal Investigator - Christian Vestergaard
Dermato-verenologisk afdeling S, Denmark
Principal Investigator - Christos C Zouboulis
Dessau Medical Center, Department of Dermatology, Venerology, Allergology and Immunology, Germany
Principal Investigator - E P Prens
Erasmus MC, Rotterdam, Netherlands
Principal Investigator - Falk G Bechara
Ruhr-University Bochum, Germany
Principal Investigator - Gregor Jemec
Dermatologisk Afdeling, Roskilde, Denmark
Principal Investigator - Jan Mekkes
Dermatologie AMC, Amsterdam, NL
Principal Investigator - Lars French
Zurich University Hospital, Switzerland
Principal Investigator - R Hunger
University of Bern, Switzerland
Principal Investigator - Sylke Schneider-Burrus
Psoriasis Research and Treatment Center, Charité hospital, Berlin, Germany
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Roskilde, Denmark
- Novartis Investigative Site
Berlin, Germany
- Novartis Investigative Site
Bochum, Germany
- Novartis Investigative Site
Groningen, Netherlands
- Novartis Investigative Site
Rotterdam, Netherlands
- Novartis Investigative Site
Basel, Switzerland
- Novartis Investigative Site
Zurich, Switzerland
- Novartis Investigative Site
Los Angeles, California, United States
- Novartis Investigative Site
Ormond Beach, Florida, United States
- Novartis Investigative Site
Tampa, Florida, United States
- Novartis Investigative Site
Atlanta, Georgia, United States
- Novartis Investigative Site
Indianapolis, Indiana, United States
- Novartis Investigative Site
Rockville, Maryland, United States
- Novartis Investigative Site
Boston, Massachusetts, United States
- Novartis Investigative Site
Omaha, Nebraska, United States
- Novartis Investigative Site
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Apr 2015
- Primary completion
- 23 Nov 2016
- Completion
- 23 Nov 2016
- Last update posted
- 13 Jul 2022
- Registered enrollment
- 66
- Registry id
- NCT02421172
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.